Rothschild & Co Redburn downgraded Medpace (MEDP) to Neutral from Buy with a price target of $474, up from $342. The firm cites valuation for the downgrade following the stock’s recent rally.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP: